|
From Goldman Sachs
---
A Business Evaluation
of Uprima
 "We
believe that Uprima will offer physicians and patients an alternative
to Pfizer's Viagra. Uprima offers an advantage in its quick onset of action,
which is in the 15-30 minute range. This compares to at least 45 minutes
for Viagra. The challenge for Uprima will clearly be the potential for
side effects. Nonetheless, the market for MED is growing rapidly with
Viagra's 1999 sales approximating $1 billion. According to Street estimates,
Viagra is expected to grow 15%-20% in 2000 towards $1.2 billion. As a
result, TAP has an excellent opportunity to offer a therapy for patients
that cannot use Viagra. We are maintaining our 2001 and 2002 sales forecasts
for Uprima of $50 million and $150 million, respectively. We believe that
our Uprima forecasts are achievable, and potentially conservative. And
while not a blockbuster for the company, Uprima will add some needed incremental
top-line for the company in the near-term."
----From office of GS drug analyst Cynthia Beach (4/11/2000)
BACK
|
